Zealand meddeler de første resultater fra Helsinns fase IIb-studie med elsiglutid til forebyggelse af kemoterapi-induceret diarré hos patienter med tarmkræft
May 04, 2016 12:55 ET
|
Zealand Pharma A/S
I studiet reducerede elsiglutid forekomsten af kemoterapi-induceret diarré hos tarmkræftpatienter i behandling med 5-FU-baseret kemoterapi, men ikke tilstrækkeligt til at opnå statistisk...
Zealand announces top-line results of Helsinn’s Phase IIb trial with elsiglutide for the prevention of chemotherapy-induced diarrhea in colorectal cancer patients
May 04, 2016 12:55 ET
|
Zealand Pharma A/S
In the trial, elsiglutide reduced the incidence of chemotherapy-induced diarrhea in colorectal cancer patients receiving 5-FU based chemotherapy regimens, but not sufficiently to meet the primary...
Notice of Zealand’s interim report for Q1 2016 and related conference call
May 04, 2016 10:18 ET
|
Zealand Pharma A/S
On the day of release, Wednesday 18 May 2016 at 9.00am CET, Zealand’s senior management will host a conference call. The conference call can be accessed via live audio webcast from Zealand’s...
Dato for offentliggørelse af Zealands delårsrapport for 1. kvt. 2016 samt tilhørende telefonkonference
May 04, 2016 10:18 ET
|
Zealand Pharma A/S
På dagen for offentliggørelse, onsdag 18. maj 2016 kl. 9.00 afholder Zealands ledelse en telefonkonference. Telefonkonferencen kan også tilgås via webbaseret lydspor fra Zealands hjemmeside....
Zealand announces the total number of shares and voting rights in the company as of 30 April 2016
April 30, 2016 06:02 ET
|
Zealand Pharma A/S
Copenhagen, 30 April 2016 - In accordance with Section 6 of the Danish Statutory Order on Issuers' Disclosure Obligations, Zealand announces the total number of shares and voting rights in the...
Zealand annoncerer det samlede antal aktier og stemmerettigheder i selskabet pr. 30. april 2016
April 30, 2016 06:02 ET
|
Zealand Pharma A/S
København, 30. april 2016 – I henhold til § 6 i Bekendtgørelse om udsteders oplysningsforpligtelser meddeler Zealand det samlede antal aktier og stemmerettigheder i selskabet ved udgangen af en...
Zealand reports Lyxumia® royalty revenue for Q1 2016 and submission by Sanofi of the fixed-ratio combination of insulin glargine (Lantus®) and lixisenatide for European registration
April 29, 2016 01:34 ET
|
Zealand Pharma A/S
Royalty revenue to Zealand from Sanofi’s sales of Lyxumia® (lixisenatide) amounted to DKK 6.5 million / EUR 0.9 million in Q1 2016
In March 2016, Sanofi submitted as planned the fixed-ratio...
Zealand rapporterer Lyxumia®-licensindtægter for 1. kvt. 2016 og, at Sanofi har indsendt præmix-kombinationen af insulin glargin (Lantus®) og lixisenatid til registrering i Europa
April 29, 2016 01:34 ET
|
Zealand Pharma A/S
Licensindtægter til Zealand fra Sanofis salg af Lyxumia® (lixisenatid) udgjorde 6,5 mio. kr. i 1. kvartal 2016
I marts 2016 indsendte Sanofi som planlagt en registreringsansøgning i Europa...
Forløb af Zealands ordinære generalforsamling 2016
April 19, 2016 13:33 ET
|
Zealand Pharma A/S
Alle fremsatte forslag blev godkendt af generalforsamlingen
Efter generalforsamlingen konstituerede bestyrelsen sig med Martin Nicklasson fortsættende som formand
København, den...
Passing of Zealand’s Annual General Meeting in 2016
April 19, 2016 13:33 ET
|
Zealand Pharma A/S
All the proposals put forward were adopted by the General Meeting
Following the General Meeting, the Board of Directors constituted itself with Martin Nicklasson continuing as Chairman of the...